Fed Regist. 1991 Nov 21;56(225):58758-9.
The Food and Drug Administration (FDA) is amending the regulations for delegations of authority relating to premarket approval of products that are or contain a biologic, a device, or a drug. The amendment grants directors, deputy directors, and certain other supervisory personnel in the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Center for Drug Evaluation and Research (CDER) reciprocal premarket approval authority to approve such products.
美国食品药品监督管理局(FDA)正在修订关于对生物制品、器械或药品相关产品的上市前批准的授权委托规定。该修订赋予生物制品评估和研究中心(CBER)、器械和放射健康中心(CDRH)以及药品评估和研究中心(CDER)的主任、副主任和某些其他监督人员相互的上市前批准权,以批准此类产品。